Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Seruga

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Current Oncology (Toronto, Ont.)|May 30, 2009
Targeted therapies for renal cell carcinoma: more gains from using them againH K Gan, B Seruga, J J Knox
Current Oncology (Toronto, Ont.)|May 30, 2009
Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancerB Seruga, H K Gan, J J Knox
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2012
How valid are claims for synergy in published clinical studies?A Ocana, E Amir, C Yeung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 10, 2009
Global drug development in cancer: a cross-sectional study of clinical trial registriesB Seruga, P C Hertz, L W Le, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 4, 2018
Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysisR Barua, A J Templeton, B Seruga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2012
Comparison of absolute benefits of anticancer therapies determined by snapshot and area methodsB Seruga, G R Pond, P C Hertz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2009
Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancerB Seruga, P C Hertz, L Wang, et al.
Cancer Treatment Reviews|February 2, 2016
Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapiesA Srikanthan, F Vera-Badillo, J Ethier, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 7, 2015
Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical TrialsH Y AlHashem, M Al-Mubarak, F E Vera-Badillo, et al.
Breast Cancer Research and Treatment|September 8, 2012
A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancerJ Vardy, G Pond, A Dodd, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Current Oncology (Toronto, Ont.)|May 30, 2009
Targeted therapies for renal cell carcinoma: more gains from using them againH K Gan, B Seruga, J J Knox
Current Oncology (Toronto, Ont.)|May 30, 2009
Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancerB Seruga, H K Gan, J J Knox
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2012
How valid are claims for synergy in published clinical studies?A Ocana, E Amir, C Yeung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 10, 2009
Global drug development in cancer: a cross-sectional study of clinical trial registriesB Seruga, P C Hertz, L W Le, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 4, 2018
Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysisR Barua, A J Templeton, B Seruga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2012
Comparison of absolute benefits of anticancer therapies determined by snapshot and area methodsB Seruga, G R Pond, P C Hertz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2009
Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancerB Seruga, P C Hertz, L Wang, et al.
Cancer Treatment Reviews|February 2, 2016
Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapiesA Srikanthan, F Vera-Badillo, J Ethier, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 7, 2015
Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical TrialsH Y AlHashem, M Al-Mubarak, F E Vera-Badillo, et al.
Breast Cancer Research and Treatment|September 8, 2012
A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancerJ Vardy, G Pond, A Dodd, et al.
Pageof 2